MacroGenics (MGNX) Analysts See $-1.02 EPS; Avalon Advisors Has Lowered Novartis Ag (NVS) Stake By $907,272

July 13, 2017 - By Adrian Erickson

Analysts expect MacroGenics Inc (NASDAQ:MGNX) to report $-1.02 EPS on August, 2.They anticipate $2.14 EPS change or 191.07% from last quarter’s $1.12 EPS. After having $-1.08 EPS previously, MacroGenics Inc’s analysts see -5.56% EPS growth. About 24,344 shares traded. MacroGenics Inc (NASDAQ:MGNX) has declined 9.76% since July 13, 2016 and is downtrending. It has underperformed by 26.46% the S&P500.

Avalon Advisors Llc decreased Novartis Ag (NVS) stake by 32.07% reported in 2016Q4 SEC filing. Avalon Advisors Llc sold 12,601 shares as Novartis Ag (NVS)’s stock rose 4.17%. The Avalon Advisors Llc holds 26,691 shares with $1.94M value, down from 39,292 last quarter. Novartis Ag now has $219.65B valuation. The stock declined 1.01% or $0.84 reaching $82.37 per share. About 700,646 shares traded. Novartis AG (ADR) (NYSE:NVS) has risen 7.67% since July 13, 2016 and is uptrending. It has underperformed by 9.03% the S&P500.

MacroGenics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing monoclonal antibody therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The company has market cap of $615.18 million. The Firm develops therapeutic product candidates using its antibody technology platforms and also in collaboration with other biopharmaceutical companies. It currently has negative earnings. It has a pipeline of product candidates in human clinical testing, primarily as treatments for different types of cancers, which are created using its technology platforms.

Among 7 analysts covering MacroGenics (NASDAQ:MGNX), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. MacroGenics had 11 analyst reports since August 6, 2015 according to SRatingsIntel. The rating was upgraded by Citigroup to “Buy” on Monday, October 19. Citigroup downgraded the stock to “Neutral” rating in Thursday, August 4 report. The stock of MacroGenics Inc (NASDAQ:MGNX) earned “Buy” rating by Zacks on Monday, August 10. The firm has “Buy” rating by SunTrust given on Tuesday, December 20. The firm has “Neutral” rating given on Thursday, September 17 by Citigroup. The rating was initiated by Morgan Stanley on Thursday, February 25 with “Equal-Weight”. The firm has “Buy” rating given on Thursday, August 6 by Stifel Nicolaus. The stock of MacroGenics Inc (NASDAQ:MGNX) has “Buy” rating given on Thursday, February 18 by Janney Capital.

Since June 5, 2017, it had 0 buys, and 1 insider sale for $100,000 activity. Wigginton Jon Marc sold $100,000 worth of MacroGenics Inc (NASDAQ:MGNX) on Monday, June 5.

Investors sentiment decreased to 1 in Q4 2016. Its down 0.43, from 1.43 in 2016Q3. It dived, as 15 investors sold MacroGenics Inc shares while 40 reduced holdings. 16 funds opened positions while 39 raised stakes. 27.48 million shares or 1.39% less from 27.87 million shares in 2016Q3 were reported. Intll Grp Incorporated has invested 0% in MacroGenics Inc (NASDAQ:MGNX). Moreover, Prelude Ltd Company has 0% invested in MacroGenics Inc (NASDAQ:MGNX). Federated Invsts Pa accumulated 190,892 shares. Everpoint Asset Mgmt holds 0.02% or 60,000 shares in its portfolio. Royal Financial Bank Of Canada has 1,711 shares for 0% of their portfolio. Loring Wolcott & Coolidge Fiduciary Advisors Ltd Liability Partnership Ma holds 0% of its portfolio in MacroGenics Inc (NASDAQ:MGNX) for 213 shares. 155,000 are held by Rhenman Ptnrs Asset Management. Morgan Stanley, a New York-based fund reported 94,697 shares. Blackrock holds 0% or 2,503 shares. Rhumbline Advisers holds 36,128 shares or 0% of its portfolio. Blackrock Inv Limited Liability Corp accumulated 124,466 shares. Muhlenkamp accumulated 0.08% or 12,803 shares. Invesco Ltd holds 16,501 shares or 0% of its portfolio. Clearbridge Investments Ltd Company reported 3,944 shares or 0% of all its holdings. Pinnacle Assoc, a New York-based fund reported 652,777 shares.

Among 15 analysts covering Novartis Ag (NYSE:NVS), 4 have Buy rating, 3 Sell and 8 Hold. Therefore 27% are positive. Novartis Ag had 26 analyst reports since July 28, 2015 according to SRatingsIntel. JP Morgan maintained the stock with “Neutral” rating in Wednesday, April 19 report. The company was downgraded on Friday, April 1 by UBS. The stock of Novartis AG (ADR) (NYSE:NVS) earned “Underperform” rating by Credit Suisse on Wednesday, July 5. On Thursday, November 10 the stock rating was upgraded by Argus Research to “Buy”. The firm earned “Neutral” rating on Tuesday, January 3 by JP Morgan. The firm earned “Neutral” rating on Friday, March 24 by JP Morgan. Chardan Capital Markets maintained it with “Buy” rating and $92 target in Monday, October 10 report. The firm has “Neutral” rating given on Friday, June 16 by J P Morgan Chase Co. Leerink Swann downgraded the stock to “Market Perform” rating in Wednesday, March 23 report. The company was downgraded on Wednesday, January 11 by Credit Suisse.

Analysts await Novartis AG (ADR) (NYSE:NVS) to report earnings on July, 18. They expect $1.18 EPS, down 3.28% or $0.04 from last year’s $1.22 per share. NVS’s profit will be $3.15 billion for 17.45 P/E if the $1.18 EPS becomes a reality. After $1.13 actual EPS reported by Novartis AG (ADR) for the previous quarter, Wall Street now forecasts 4.42% EPS growth.

Avalon Advisors Llc increased Abb Ltd Sponsored Adr (NYSE:ABB) stake by 52,877 shares to 84,639 valued at $1.78M in 2016Q4. It also upped Boeing Company Cmn (NYSE:BA) stake by 8,510 shares and now owns 249,244 shares. Zions Bancorp (NASDAQ:ZION) was raised too.